Pharmaceuticals News and Research

RSS

High court seems skeptical that biotech firm can patent human genes

Supreme Court justices seemed to express skepticism Monday that a biotech company can patent human genes isolated from the body that signal a greater likelihood of ovarian or breast cancer.

17 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

First Edition: April 16, 2013

Today's headlines include coverage of the Supreme Court oral arguments regarding whether patents should be granted for human genes.

16 Apr 2013

Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France.

16 Apr 2013

Production of synthetic artemisinin an attack against farmers currently growing the plant

"On Thursday, the founder of Amyris Biotech triumphantly announced production of 70 million doses of the anti-malarial compound artemisinin," Jim Thomas, research program director for ETC group, a technology watchdog that works with farmers' organizations, writes in The Guardian's "Poverty Matters" blog.

16 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Drug makers must change R&D practices or patent disputes will continue

"[T]he impact of [a decision by the Supreme Court in India to disallow a new patent for an updated version of Novartis' cancer drug Glivec] will likely be broader than just that issue, escalating a long-simmering fight over patented cancer medications in emerging markets," Thomas Bollyky, senior fellow for global health, economics, and development at the Council on Foreign Relations and an adjunct professor of law at Georgetown University, writes in an Atlantic opinion piece.

15 Apr 2013

FDA grants Fast Track designation to Elorac's naloxone topical lotion

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the U.S. Food and Drug Administration has granted Fast Track designation to the Company's naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma.

15 Apr 2013

FDA approves Taro's NDA for Topicort Topical Spray

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its New Drug Application Topicort (desoximetasone) Topical Spray, 0.25%.

15 Apr 2013

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.

15 Apr 2013

Researchers create complete visual map of telomerase enzyme

Like finally seeing all the gears of a watch and how they work together, researchers from UCLA and UC Berkeley have, for the first time ever, solved the puzzle of how the various components of an entire telomerase enzyme complex fit together and function in a three-dimensional structure.

15 Apr 2013

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease.

15 Apr 2013

Research roundup: Lesson for insurance exchanges from Europe; Health care disparities among Hispanics

As states and the federal government begin creating insurance exchanges under the health law, researchers highlight several lessons from Switzerland and the Netherlands.

15 Apr 2013

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

Sanofi launches large-scale production of artemisinin for malaria

Twelve years after a breakthrough discovery in his University of California, Berkeley, laboratory, professor of chemical engineering Jay Keasling is seeing his dream come true.

12 Apr 2013

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Aileron Therapeutics, Inc. today announced new preclinical data demonstrating that ATSP-9172, its Stapled Peptide inhibitor of HIF-1α-dependent transcription, exhibits on-target binding activity, favorable pharmacokinetic properties and potent in vivo efficacy in a human prostate cancer model.

12 Apr 2013

Some drug makers cut payments, meals provided to doctors

Two pharmaceutical companies that are among the biggest payers of fees to doctors reduced such spending last year by double-digit percentages, as greater transparency sheds light on the hundreds of millions of dollars the industry pays physicians for marketing and research efforts (Loftus, 4/10).

12 Apr 2013

New research shows safety can be improved for people participating in medical experiments

In almost 90 per cent of cases, novel drugs tested on humans by pharmaceutical companies do not work as intended and must be scrapped. Often the drugs do not work, while at worst, test subjects die. New research from the University of Southern Denmark now shows that this number can be reduced.

12 Apr 2013

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.

12 Apr 2013

First Edition: April 11, 2013

Today's headlines include details regarding how Medicare and Medicaid, as well as funding for the health law's implementation, fared in President Barack Obama's budget plan.

11 Apr 2013

Pharmaceuticals News and Research

High court seems skeptical that biotech firm can patent human genes

COPD phase III study by Almirall and Forest Laboratories announces positive results

First Edition: April 16, 2013

Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Production of synthetic artemisinin an attack against farmers currently growing the plant

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Drug makers must change R&D practices or patent disputes will continue

FDA grants Fast Track designation to Elorac's naloxone topical lotion

FDA approves Taro's NDA for Topicort Topical Spray

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Researchers create complete visual map of telomerase enzyme

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Research roundup: Lesson for insurance exchanges from Europe; Health care disparities among Hispanics

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Sanofi launches large-scale production of artemisinin for malaria

ATSP-9172 exhibits on-target binding activity in human prostate cancer model

Some drug makers cut payments, meals provided to doctors

New research shows safety can be improved for people participating in medical experiments

Sorbent Therapeutics starts patient dosing in Phase 2b clinical trial of CLP-1001

First Edition: April 11, 2013

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence